Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar, K., Walker, M.M., Jones, L.M., Bolanos, L.C., Hueneman, K., Wunderlich, M., Jiang, J.K., Wilson, K.M., Zhang, X., Sutter, P., Wang, A., Xu, X., Choi, K., Tawa, G., Lorimer, D., Abendroth, J., O'Brien, E., Hoyt, S.B., Berman, E., Famulare, C.A., Mulloy, J.C., Levine, R.L., Perentesis, J.P., Thomas, C.J., Starczynowski, D.T.(2019) Sci Transl Med 11
- PubMed: 31484791 
- DOI: 10.1126/scitranslmed.aaw8828
- Primary Citation of Related Structures:  
6MOM - PubMed Abstract: 
Targeted inhibitors to oncogenic kinases demonstrate encouraging clinical responses early in the treatment course; however, most patients will relapse because of target-dependent mechanisms that mitigate enzyme-inhibitor binding or through target-independent mechanisms, such as alternate activation of survival and proliferation pathways, known as adaptive resistance ...